SAN DIEGO--(BUSINESS WIRE)--May 10, 2006--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH - News) today announced financial results for the first quarter of 2006. For the quarter ended March 31, 2006, the Company reported a net loss of $6.9 million (or $0.30 per share), compared to a net loss of $6.8 million (or $0.35 per share) in the first quarter of 2005. Included in the net loss for the first quarter of 2006 was $1.3 million of stock-based compensation expense related to the adoption of SFAS No. 123R. There was no such comparable expense in 2005.
